<DOC>
	<DOCNO>NCT01044238</DOCNO>
	<brief_summary>This 4-year study investigate effectiveness methylphenidate initiate sustain abstinence methamphetamine dependent individual . Approximately 90 participant seek treatment methamphetamine dependence enrol study initial 2 week establish clinic compliance . During compliance phase , participant receive incentive clinic attendance . After meet clinic attendance requirement , participant randomize placebo ( n = 45 ) active study medication ( n = 45 ) condition , give 18mg/daily study drug placebo one week , follow 36mg/daily study drug/placebo second week . Finally , participant stabilize 54mg/daily study drug/placebo remainder study . Placebo participant give placebo medication prepare appear identical active medication . In addition , randomization , participant receive motivational incentive methamphetamine-negative urine test begin weekly cognitive behavioral therapy ( CBT ) provide duration study .</brief_summary>
	<brief_title>Methylphenidate Treat Methamphetamine Dependence</brief_title>
	<detailed_description />
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Be seek treatment MA use disorder ; 2 . Be 1855 year age ; 3 . Meet DSMIVTR criterion MA dependence assess Mini International Neuropsychological Interview ( MINI ) ; 1 . Have history evidence suggestive seizure brain injury ; 2 . Have know hypersensitivity previous medically adverse reaction methylphenidate ; 3 . Have neurological psychiatric disorder , psychosis , bipolar illness , motor tic , Tourette 's syndrome , major depression ; organic brain disease dementia ; mark anxiety , tension agitation ; psychiatric disorder would require ongoing treatment would make study compliance difficult ; 4 . Have evidence clinically significant heart disease hypertension determine medical history physical examination , include preexist heart failure , recent myocardial infarction , ventricular arrhythmia , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease . 5 . Have family history firstdegree relatives early cardiovascular morbidity mortality , determine medical history ; 6 . Have evidence untreated unstable medical illness include : neuroendocrine , autoimmune , renal , hepatic , active infectious disease ( HIV ) ; 7 . Have clinically significant abnormal vital sign ; 8 . Have clinically significant abnormal hematology chemistry laboratory test [ e.g . liver function test ( total bilirubin , ALT , AST , alkaline phosphatase ) , kidney function test ( creatinine BUN ) ] ; 9 . Have baseline ECG demonstrate clinically significant abnormality ; 10 . Have know preexist severe gastrointestinal narrowing , 11 . Be pregnant nursing . Females must either unable conceive ( i.e. , surgically sterilize , sterile , postmenopausal ) use reliable form contraception include hormonal ( oral , DepoProvera Nuvaring ) , intrauterine devise , sterilization double barrier method ( simultaneous use two barrier method condom , diaphragm , spermicide ) ; 12 . A history glaucoma ; 13 . Use medication Clonidine , coumarin anticoagulant , anticonvulsant ( Phenobarbital , phenytoin , primidone ) , vasopressor agent , antidepressant ( tricyclic selective serotonin reuptake inhibitor ) , . Also , current use MAO inhibitor , use within 14 day enrollment ; 14 . Have medical condition would , opinion study physician , make participation difficult unsafe .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>methamphetamine</keyword>
	<keyword>methylphenidate</keyword>
	<keyword>clinical trial</keyword>
	<keyword>random assignment</keyword>
	<keyword>double blind</keyword>
	<keyword>abstinence</keyword>
	<keyword>reduction methamphetamine use</keyword>
</DOC>